Table 1.

Overview of 21 studies included for reviewa

ReferenceNClinical Presentation/DiagnosisTreatment before RituximabProteinuria before Rituximab (mean g/24h if n > 1)Renal Function before Rituximab (mean if n > 1)f
Remuzzi et al. (2002)8Idiopathic MN with persistent NSFull-dose ACE-I for mean 29.7 mo8.6Cr 1.4 mg/dl
Ruggenenti et al. (2003)8bIdiopathic MN with persistent NSFull-dose ACE-I for mean 29.7 mo8.6Cr 1.4 mg/dl
Ratanatharathorn et al. (2003)1Secondary MN after hematopoietic stem cell transplantTacrolimus, methylprednisolone, and MMF over 8 mo15.0Not reported
Fra et al. (2003)1Secondary MN in setting of SLE with persistent NSHigh-dose prednisone (cumulative dose 13.7 g) and cyclophosphamide (cumulative dose 15.7 g) over 9 mo2.0Cr 0.8 mg/dl
Rossi et al. (2005)1Idiopathic MNMethylprednisolone 2 mg/kg/d for 2 wk, then 5 mg/kg/d for 1 wk11.0Normal range
Rao (2005)2Secondary MN after hematopoietic stem cell transplantNone (n = 1); prednisone, MMF, and ARB for 3 mo (n = 1)9.5Cr 1.1 mg/dl
Srinivasan et al. (2005)2Secondary MN after hematopoietic stem cell transplantCyclosporine (n = 2) and prednisone (n = 1)21.0CrCl 47.9 ml/min
Jacobson et al. (2006)1Secondary MN in setting of SLE with persistent NSCyclophosphamide, prednisolone, cyclosporine, and MMF over >33 mo5.3Cr 2.7 mg/dl
Cobo et al. (2006)1Idiopathic MN with persistent NSACE-I + ARB for 8 mo, then steroids and chlorambucil for 5 mo7.3Cr 1.0 mg/dl
Gallon and Chhabra (2006)1Recurrent idiopathic MN after kidney transplantFull-dose ACE-I for 1 mo on top of maintenance immunosuppression with MMF and tacrolimus16.0Cr 1.8 mg/dl
Reddy et al. (2006)1Secondary MN after hematopoietic stem cell transplantMethylprednisolone8.0Not reported
Ruggenenti et al. (2006)23cIdiopathic MN with persistent NSACE-I for at least 6 mo9.1Cr 1.4 mg/dl
Terrier et al. (2007)1Secondary MN after hematopoietic stem cell transplantACE-I, corticosteroids, and MMF8.2CrCl 57 ml/min
Cravedi et al. (2007)12dIdiopathic MN with persistent NSACE-I for at least 6 mo10.3Cr 1.4 mg/dl
Pansini et al. (2007)1Secondary MN in setting of HCV with relapse on NSFull-dose ACE-I10.4Cr 0.8 mg/dl
Fervenza et al. (2008)15Idiopathic MN with persistent NSACE-I + ARB for at least 4 mo (n = 15); prednisone alone (n = 2); prednisone and alkylating agent (n = 2); cyclosporine (n = 2); MMF (n = 1)13.0Cr 1.4 mg/dl
Ferrannini et al. (2008)1Secondary MN after hematopoietic stem cell transplantMethylprednisolone 1 g/d for 3 d, then prednisone decreased until 0.5 mg/kg/d35.2Cr 0.9 mg/dl
Troxell et al. (2008)4Secondary MN after hematopoietic stem cell transplantPrednisone alone (n = 1); prednisone and MMF (n = 1)10.3Cr 1.3 mg/dl
Weclawiak et al. (2008)1Recurrent idiopathic MN after kidney transplantACE-I for 18 mo, then ACE-I and ARB for 7 mo, in addition to maintenance immunosuppression with prednisone, MMF, and cyclosporine10.8Cr 1.5 mg/dl
Pixley et al. (2008)1Secondary MN in setting of rheumatoid arthritisPrednisone, chlorambucil, and MMF over 10 mo19.5Not reported
Ruggenenti et al. (2008)7eIdiopathic MN with persistent NSACE-I for at least 6 mo5.5Cr 1.0 mg/dl
  • a ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; Cr, serum or plasma creatinine; CrCl, creatinine clearance; HCV, hepatitis C virus; MMF, Mycophenolate Mofetil; MN, membranous nephropathy; NS, nephrotic syndrome; SLE, systemic lupus erythematosus.

  • b The study reported the long-term (12 mo) follow-up of the 8 patients from the earlier Remuzzi et al. (2002) study.

  • c Of the 23 subjects in this study, 8 were included in previous reports by Remuzzi et al. (2002) and Ruggenenti et al. (2003).

  • d The study used 24 historical reference patients who were previously reported in two previous studies by Ruggenenti et al. (2003, 2006).

  • e The study reviews 50 consecutive patients with MN, treated with rituximab from May 2001 to January 2007, but only reports complete data for 7 patients with complete remission who agreed to undergo repeat biopsy. The 50 patients reported in this study include patients previously described in reports by Remuzzi et al. (2002), Ruggenenti et al. (2003, 2006), and Cravedi et al. (2007).

  • f To convert Cr in mg/dl to μmol/L, multiply by 88.4; CrCl in ml/min to ml/s, multiply by 0.0167.